Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, June 23, 2024

Enhancing fall risk assessment: instrumenting vision with deep learning during walks

 It is vastly more important to create EXACT fall prevention protocols than this lazy crapola of 'assessments'! But your doctor should be using inertial measurement units(IMUs) to objectively quantify your gait deficits. And then map those deficits to EXACT REHAB PROTOCOLS!

Enhancing fall risk assessment: instrumenting vision with deep learning during walks

Abstract

Background

Falls are common in a range of clinical cohorts, where routine risk assessment often comprises subjective visual observation only. Typically, observational assessment involves evaluation of an individual’s gait during scripted walking protocols within a lab to identify deficits that potentially increase fall risk, but subtle deficits may not be (readily) observable. Therefore, objective approaches (e.g., inertial measurement units, IMUs) are useful for quantifying high resolution gait characteristics, enabling more informed fall risk assessment by capturing subtle deficits. However, IMU-based gait instrumentation alone is limited, failing to consider participant behaviour and details within the environment (e.g., obstacles). Video-based eye-tracking glasses may provide additional insight to fall risk, clarifying how people traverse environments based on head and eye movements. Recording head and eye movements can provide insights into how the allocation of visual attention to environmental stimuli influences successful navigation around obstacles. Yet, manual review of video data to evaluate head and eye movements is time-consuming and subjective. An automated approach is needed but none currently exists. This paper proposes a deep learning-based object detection algorithm (VARFA) to instrument vision and video data during walks, complementing instrumented gait.

Method

The approach automatically labels video data captured in a gait lab to assess visual attention and details of the environment. The proposed algorithm uses a YoloV8 model trained on with a novel lab-based dataset.

Results

VARFA achieved excellent evaluation metrics (0.93 mAP50), identifying, and localizing static objects (e.g., obstacles in the walking path) with an average accuracy of 93%. Similarly, a U-NET based track/path segmentation model achieved good metrics (IoU 0.82), suggesting that the predicted tracks (i.e., walking paths) align closely with the actual track, with an overlap of 82%. Notably, both models achieved these metrics while processing at real-time speeds, demonstrating efficiency and effectiveness for pragmatic applications.

Conclusion

The instrumented approach improves the efficiency and accuracy of fall risk assessment by evaluating the visual allocation of attention (i.e., information about when and where a person is attending) during navigation, improving the breadth of instrumentation in this area. Use of VARFA to instrument vision could be used to better inform fall risk assessment by providing behaviour and context data to complement instrumented e.g., IMU data during gait tasks. That may have notable (e.g., personalized) rehabilitation implications across a wide range of clinical cohorts where poor gait and increased fall risk are common.

Introduction

Falls can lead to loss of independence and even death [1, 2]. Identifying those at risk of falling is an important clinical task often conducted in e.g., those with visual impairment [3], and the elderly [4,5,6]. Equally, fall risk assessment is of notable importance and pragmatically useful in people with a movement disorder, such as Parkinson’s disease (PD) [7,8,9] or Stroke [10,11,12,13] due to observable functional deficits in motor control. Additionally, assessing fall risk is equally important during pregnancy [14] where a third of pregnant women may fall [15]. In fact, there is a significant increase in falls from pre-pregnancy to the 3rd trimester which cannot be fully explained by morphological [16] or biomechanical [17] changes.

A comprehensive fall risk assessment is multifactorial and a time-consuming process including but not limited to medication review, cognitive screening, detailing a history of falls, as well as evaluating gait, balance [18], and environmental hazards or hazardous activities that have been documented in some cases to be responsible for 50% of falls [19]. For timeliness in many settings, assessing gait alone is usually conducted to evaluate intrinsic fall risk [20]. That is convenient as gait is a good marker of global health [21] and fundamental to many activities of daily life [1]. Consequently, a gait assessment with positive outcomes from subjective evaluation (by an assessor) provides insight into the patient’s independence and ability to ambulate with minimal fall risk. As described, an assessment is typically conducted by manual observation alone, where an assessor examines a person’s gait during a scripted task (i.e., walking protocol). Often, a protocol may include navigating (walking around or over) obstacles [22,23,24,25], deliberately challenging the person by increasing gait demands [26]. Yet, that also places extra burden on the assessor, challenging them to carefully observe the person’s gait during a more complex task. Instrumentation is needed to optimize assessment protocols while providing high resolution objective fall risk data.

The integration of digital technology as an objective standard in fall risk is not routine. While digital tools may provide clinicians with high-resolution data to potentially aid in determining a patient’s fall risk, there is still ongoing work to be done in understanding their full utility and developing appropriate methods. In recent years, technology has matured to include a wide selection of digital tools. Of course, 3D motion capture systems are a perceived gold/reference standard for human movement analysis, but it lacks practicality and deployment in habitual settings. Moreover, reflective markers require timely application. In contrast, wearable devices (i.e., inertial measurement units, IMUs) are quickly attached and provide clinically relevant gait characteristics to a millisecond resolution in any environment [27,28,29,30].

An objective gait assessment to inform fall risk is usually conducted within a laboratory with a single IMU on the lower back [30]. Typically, participants are then asked to undertake a protocol representing walking challenges in daily life [31, 32], like obstacle crossing [25]. However, a key IMU limitation is the provision of inertial gait data only without any insights into navigating behavior and visual attention allocation to environmental/extrinsic details. Accordingly, there is no absolute clarity to understand how gait and fall risk is influenced by other intrinsic (e.g., visual attention) or extrinsic (e.g., obstacles) factors. For example, a comprehensive instrumented assessment would better understand how those being assessed allocate visual attention along their walking path for safe navigation while also determining the role of attention when e.g., peripheral obstacles cause a distraction. Supplementing IMU data with video data from video-based eye tracking wearable glasses could better define intrinsic and extrinsic factors, providing a contemporary and pragmatic approach to fall risk assessment with easily attached wearables. (Indeed, eye tracking offers an avenue for exploring neurocognitive changes as a reason for increased falls incidence.)

Commercial eye tracking glasses capture high quality video data and often in the standardized MP4 format with a resolution of 1920 × 1080. The video contains a superimposed crosshair to display eye location. Accordingly, videos contain data on the general environment and specific objects of where the wearer is looking but data processing of eye-tracker videos is extremely time consuming and needs to be automated to allow clinical application [33]. Including eye tracking (to identify an object/obstacles of interest) with IMU data during a range of simulated free-living tasks (e.g., obstacle crossing) would provide a novel approach for simultaneously instrumenting visual attention during gait within a fall risk assessment. To accomplish this, a suitable methodology to instrument visual attention from video data must first be established as none currently exists. Accordingly, a novel vision-aided fall risk assessment (VAFRA) is proposed in this study.

More at link.

Comparing Outcomes of Thrombectomy Versus Intravenous Thrombolysis Based on Middle Cerebral Artery M2 Occlusion Features

 So everything here was a failure, nobody got to 100% recovery! Damn it all, that is the only goal in stroke that survivors want! GET THERE!

Comparing Outcomes of Thrombectomy Versus Intravenous Thrombolysis Based on Middle Cerebral Artery M2 Occlusion Features

Originally publishedhttps://doi.org/10.1161/STROKEAHA.123.044986Stroke. 2024;55:1592–1600

Abstract

BACKGROUND:

Current evidence provides limited support for the superiority of endovascular thrombectomy (EVT) in patients with M2 segment middle cerebral artery occlusion. We aim to investigate whether imaging features of M2 segment occlusion impact the effectiveness of EVT.

METHODS:

We conducted a retrospective cohort study from January 2017 to January 2022, drawing data from the CASE II registry (Computer-Based Online Database of Acute Stroke Patients for Stroke Management Quality Evaluation), which specifically documented patients with acute ischemic stroke presenting with M2 segment occlusion undergoing reperfusion therapy. Patients were stratified into the intravenous thrombolysis (IVT) group (IVT alone) and EVT group (IVT plus EVT or EVT alone). The primary outcome was a modified Rankin Scale score 0 to 2 at 90 days. Secondary outcomes included additional thresholds and distribution of modified Rankin Scale scores, 24-hour recanalization, early neurological deterioration, and relevant complications during hospitalization. Safety outcomes encompassed intracranial hemorrhagic events at 24 hours and mortality at 90 days. Binary logistic regression analyses with propensity score matching were used. Subgroup analyses were performed based on the anatomic site of occlusion, including right versus left, proximal versus distal, dominant/co-dominant versus nondominant, single versus double/triple branch(es), and anterior versus central/posterior branch.

RESULTS:

Among 734 patients (43.3% were females; median age, 73 years) with M2 segment occlusion, 342 (46.6%) were in the EVT group. Propensity score matching analysis revealed no statistical difference in the primary outcome (odds ratio, 0.860 [95% CI, 0.611–1.209]; P=0.385) between the EVT group and IVT group. However, EVT was associated with a higher incidence of subarachnoid hemorrhage (odds ratio, 6.655 [95% CI, 1.487–29.788]; P=0.004) and pneumonia (odds ratio, 2.015 [95% CI, 1.364–2.977]; P<0.001). Subgroup analyses indicated that patients in the IVT group achieved better outcomes(NOT RECOVERY!) when presenting with right, distal, or nondominant branch occlusion (Pall interaction<0.05).

CONCLUSIONS:

Our study showed similar efficiency of EVT versus IVT alone in acute M2 segment middle cerebral artery occlusion. This suggested that only specific patient subpopulations might have a potentially higher benefit of EVT over IVT alone.

REGISTRATION:

URL: https://clinicaltrials.gov; Unique identifier: NCT04487340.

Five randomized clinical trials issued in 2015 have confirmed the superiority of endovascular thrombectomy (EVT) over medical management in patients of acute ischemic stroke (AIS) with anterior large vessel occlusion.1–5 However, patients with AIS enrolled in these trials mainly suffered from proximal large vessel occlusion, including internal carotid artery and M1 segment middle cerebral artery (MCA). In a meta-analysis of individual patient data from the above trials, only 95 patients were finally identified as M2 segment MCA occlusion,6 resulting in limited evidence for the efficacy of EVT in this subgroup.7

In previous post hoc studies, EVT was considered an effective measure that could improve(NOT GOOD ENOUGH!) clinical outcomes in acute M2 occlusion, when compared with the control group who received medical management, that is, intravenous thrombolysis (IVT) or antiplatelet therapy if IVT is not applicable.8–10 However, patients with AIS with M2 occlusion who received EVT achieved similar functional outcomes when compared with those with IVT alone,11 which might be due to a potentially beneficial treatment effect of IVT on more distal clot locations.12

Some M2 segment is the dominant artery supplying blood to a large portion of the MCA territory, presenting as severe neurological impairment and sizable infarction after occlusion, but is as easily accessible for EVT as the M1 segment.13–15 Hence, patients with the clot situated in the dominant M2 artery or in close proximity to the furcation are likely to experience similar benefits from EVT. We hypothesized that imaging features of M2 segment MCA occlusions might affect the efficacy and safety of EVT, either with or without IVT. In the current study, we sought to investigate whether certain anatomic characteristics of M2 segment occlusions such as location, size, anatomy, and number of vessels occluded could help select patients who would benefit more from EVT than IVT alone.

Noninvasive laser therapy shows promise in stroke treatment

 Didn't your competent? doctor figure out a protocol on this 5 years ago? NO? So you DON'T have a functioning stroke doctor? Why are you seeing them?

Noninvasive laser therapy shows promise in stroke treatment

News • Near-infrared photobiomodulation

People who experience stroke have limited therapeutic options, but new research by investigators from Massachusetts General Hospital reveals the potential for non-invasive light treatment using lasers.

The results are published in Stroke

“Unlike other approaches using chemicals, which can be toxic to our bodies, laser light is a physical parameter. It does not stay in the body after the therapy and will have little chance of causing side effects,” said co–senior author Satoshi Kashiwagi, MD, PhD, an investigator in the Department of Radiology at Massachusetts General Hospital and an assistant professor of Radiology at Harvard Medical School.

Such technology has the potential to replace the current standard therapy using chemicals, which may cause side effects

Satoshi Kashiwagi

Kashiwagi and his colleagues have been searching for new stroke therapies because the currently used combination treatment of intravenous thrombolysis and endovascular thrombectomy (the injection of clot-busting drugs plus surgical removal of a blood clot) is effective only when it is performed within a certain timeframe and is only appropriate for a fraction of patients. 

Targeting the endothelial cells that line blood vessels represents a promising therapeutic strategy because dysfunction of these cells is implicated in the development of stroke. Endothelial dysfunction is characterized by insufficient production of nitric oxide (NO), a gas that helps keep blood vessels open to allow blood to flow freely. Noting that previous research has shown that laser therapy increases NO production in endothelial cells, the Mass General research team tested the effects of laser therapy in a mouse model of stroke. 

They found that treating the head with low-power invisible laser light improved brain blood flow and decreased stroke injury. Experiments showed that mechanistically, laser treatment improved the function of blood vessels in the brain by stimulating the production of NO. 

“We discovered a new way to effectively treat stroke using laser light, a modality that is already widely used in the clinic for procedures such as Lasik eye surgery and tattoo removal, and has a well-known safety profile,” said Kashiwagi. “Thus, we expect that we could advance this technology to clinical trials relatively soon. Such technology has the potential to replace the current standard therapy using chemicals, which may cause side effects.”

Laser therapy may also be effective for a wide array of other cardiovascular diseases that are characterized by NO deficiency. 


Source: Massachusetts General Hospital

 

The ankle dorsiflexion kinetics demand to increase swing phase foot-ground clearance: implications for assistive device design and energy demands

 Doesn't your competent? doctor already have the EXACT rehab protocols to fix your dorsiflexion problems? After they have objectively defined the damage that caused the dorsiflexion problems? Oh, they didn't do an objective damage diagnosis either?

The ankle dorsiflexion kinetics demand to increase swing phase foot-ground clearance: implications for assistive device design and energy demands

Abstract

Background

The ankle is usually highly effective in modulating the swing foot’s trajectory to ensure safe ground clearance but there are few reports of ankle kinetics and mechanical energy exchange during the gait cycle swing phase. Previous work has investigated ankle swing mechanics during normal walking but with developments in devices providing dorsiflexion assistance, it is now essential to understand the minimal kinetic requirements for increasing ankle dorsiflexion, particularly for devices employing energy harvesting or utilizing lighter and lower power energy sources or actuators.

Methods

Using a real-time treadmill-walking biofeedback technique, swing phase ankle dorsiflexion was experimentally controlled to increase foot-ground clearance by 4 cm achieved via increased ankle dorsiflexion. Swing phase ankle moments and dorsiflexor muscle forces were estimated using AnyBody modeling system. It was hypothesized that increasing foot-ground clearance by 4 cm, employing only the ankle joint, would require significantly higher dorsiflexion moments and muscle forces than a normal walking control condition.

Results

Results did not confirm significantly increased ankle moments with augmented dorsiflexion, with 0.02 N.m/kg at toe-off reducing to zero by the end of swing. Tibialis Anterior muscle force incremented significantly from 2 to 4 N/kg after toe-off, due to coactivation with the Soleus. To ensure an additional 4 cm mid swing foot-ground clearance, an estimated additional 0.003 Joules/kg is required to be released immediately after toe-off.

Conclusion

This study highlights the interplay between ankle moments, muscle forces, and energy demands during swing phase ankle dorsiflexion, offering insights for the design of ankle assistive technologies. External devices do not need to deliver significantly greater ankle moments to increase ankle dorsiflexion but, they should offer higher mechanical power to provide rapid bursts of energy to facilitate quick dorsiflexion transitions before reaching Minimum Foot Clearance event. Additionally, for ankle-related bio-inspired devices incorporating artificial muscles or humanoid robots that aim to replicate natural ankle biomechanics, the inclusion of supplementary Tibialis Anterior forces is crucial due to Tibialis Anterior and Soleus co-activation. These design strategies ensures that ankle assistive technologies are both effective and aligned with the biomechanical realities of human movement.

Background

Gait impairments that increase the risk of tripping-related falls are one of the most serious consequences of ageing, stroke and many neurological and muscular conditions such as spinal cord injury, multiple sclerosis, muscular dystrophy or cerebral palsy [1,2,3]. In normal gait, the swing phase is shaped by two events, ‘Mx1’ and ‘Mx2’, representing two vertical foot displacements maxima that frame a critical moment of Minimum Toe Clearance (MTC) or Minimum Foot Clearance (MFC) (Fig. 1). MTC refers to the toe’s clearance above ground, while MFC measures the lowest part of the forefoot or shoe’s clearance from the ground. Avoiding contact with walking surface irregularities requires precisely modulated vertical displacement of the foot, especially at the swing phase Minimum Foot Clearance (MFC) event [4,5,6].

Ankle dorsiflexion is crucial for elevating the foot during swing by enabling substantial adjustments to ground clearance with relatively minor changes in ankle angles and minimal disruption to overall gait control [6,7,8]. The development of assistive technology for ankle joint dorsiflexion could play an important role in maintaining safe ground clearance and preventing tripping-related falls. Rapid progress has been observed in the development of ankle orthoses, employing advanced actuators to apply moments that can effectively assist impaired ankle dorsiflexion [9,10,11]. An essential requirement of these devices is to deliver sufficient mechanical power to ensure the necessary magnitude of ankle assistive moments. Understanding the kinetics demands of ankle joint dorsiflexion is, therefore, particularly useful for devices employing energy harvesting or utilizing lighter but also less power-demanding actuators. This understanding is the foundation for designing assistive technologies that harmonize the required ankle moments with required energy inputs.

Ankle dorsiflexion moments have been determined experimentally but more commonly in static conditions, rather than when walking. Takaiwa & Noritsugu (2008) [12] determined that 2 N.m ankle moment was required to achieve 20 degrees of ankle dorsiflexion, i.e. from − 15 degrees plantar flexion to + 5 degrees dorsiflexion. A University of Illinois design team adopted Perry and Burnfield’s (1993) [13] data to calibrate their powered AFO, employing a constant 3 N.m ankle torque throughout swing [11, 14,15,16]. Such time-dependent ankle moment measurements recorded dynamically are anticipated to be more useful in designing ankle assistive devices to more closely mimic natural gait. Kao and Ferris, (2009) [17] and Sawicki and Ferris, (2009) [18] used inverse dynamics to estimate ankle dorsiflexion moments at 1.25 m/s. They found a maximum ankle moment following toe-off of 0.016 N.m/Kg which decreased gradually until end of swing; with an ankle power range of -0.08 W/Kg to 0.05 W/Kg. Their study did not include ankle moment and power changes with increasing ankle dorsiflexion but this control feature may be useful in revealing the kinetics of high ankle dorsiflexion rotation to determine the required adequate mechanical energy input.

Consistent with the traditional focus on stance kinetics there are limited data to show ankle joint energy exchanges during swing, possibly because swing phase energy requirements are often considered less important components of lower limb joint kinetics [19, 20]. More recently it has, however, been argued that the energy consumed during swing is non-trivial, with research by Doke et al. (2005) [21] concluding that swing phase muscle activity consumes between one-quarter to one-third of total gait energy. Exploring joint work is important for understanding the mechanical energy demands of walking because joint mechanical energy is associated with the ability to perform work [22,23,24]. Ankle work can, therefore, be calculated to indicate the maximum energy demands of swing phase ankle dorsiflexion. In the study reported here we sought to determine the kinetic requirements of increasing swing phase ankle dorsiflexion by incorporating a treadmill-walking condition in which foot-ground clearance was manipulated via a continuous foot trajectory display. Subsequently, we derived the swing-phase profile of ankle joint moments and the power demands of augmenting ankle dorsiflexion.

Previous investigators have often described three swing sub-phases representing approximately 0–35%, 35–65%, and 65–100% of the swing cycle, corresponding to Initial, Mid, and Terminal swing, respectively (Fig. 1) [13, 25]. Unusual or pathological gaits may not, however, always be described adequately using these sub-phases [26] and investigation of time-dependent variables such as joint power may also require a more fine-grained analysis [27].

To explore functional variations in ankle energy demands with greater specificity, in this study we introduced three new event-dependent swing sub-phases and also calculated the time and power demands of each (Fig. 1).

In addition to determining ankle joint mechanics, foot-ankle computational modelling has been used to quantify force and power of the Tibialis Anterior (TA) as the primary dorsiflexor. A systematic review of twelve studies indicated maximum swing TA forces ranging from 1 to 4 N/kg at preferred walking speed [28] but there are important variations within sub-phases. Błażkiewicz (2013) [29] found a maximum TA force of 2 N/kg following toe-off and TA power computed by Bogey et al. (2010) [30] reached an initial negative peak of almost − 2 Watts, followed by a positive maximum of 12 Watts; those data were, however, time-normalized to the swing cycle, precluding a post-hoc work calculation. Possibly because the TA is the primary dorsiflexor, less research attention given to other ankle dorsiflexor muscles, i.e., Extensor Digitorum Longus (EDL) and Extensor Hallucis Longus (EHL). In addition to providing a more complete description of dorsiflexor kinetic contributions to ankle swing phase control, in this experiment the kinetic contributions of these three muscles were also derived.

Our objective in this study was to investigate ankle joint moments, dorsiflexor muscle forces and mechanical energy requirements of increasing swing phase ankle dorsiflexion, specifically at the high-risk Minimum Foot Clearance (MFC) event. By experimentally manipulating foot-ground clearance using a continuous feedback display, the timing and magnitude of ankle dorsiflexor moments, forces and work were modelled in response to a controlled increment in ankle dorsiflexion. It was hypothesized that relative to an unconstrained-walking control condition, greater ankle dorsiflexion would require higher ankle moments and power with increased dorsiflexor muscle forces and work.

Our findings on ankle joint and dorsiflexor muscle kinetics offer critical insights for enhancing ankle assistive technologies. Rather than increasing ankle moments, our study suggests that assistive devices should focus on providing higher mechanical energy for effective dorsiflexion. This is particularly vital for bio-inspired devices incorporating artificial muscles, where accommodating the co-activation of Tibialis Anterior and Soleus at higher dorsiflexion angles is key. These insights aim to guide the development of more efficient ankle orthoses and exoskeletons.

More at link.


Nanozymes: Potential Therapies for Reactive Oxygen Species Overproduction and Inflammation in Ischemic Stroke and Traumatic Brain Injury

 Of course your competent? doctor already knew about this way back in 2005, and got research initiated. NO? So you don't have a functioning stroke doctor, do you?

Reactive oxygen species and the modulation of stroke June 2005

The latest here:

Nanozymes: Potential Therapies for Reactive Oxygen Species Overproduction and Inflammation in Ischemic Stroke and Traumatic Brain Injury

  • Yunfan Yang
  • Zixiang Li
  • Xiaochong Fan
  • Chao Jiang
  • Junmin Wang
  • Yousef Rastegar-Kashkooli
  • Tom J. Wang
  • Junyang Wang
  • Menglu Wang
  • Nannan Cheng
  • Xiqian Yuan
  • Xuemei Chen*
  • Bing Jiang*
  • , and 
  • Jian Wang*

Cite this: ACS Nano 2024, XXXX, XXX, XXX-XXX
Publication Date:June 19, 2024
https://doi.org/10.1021/acsnano.4c03425
© 2024 American Chemical Society

Other access options

Abstract

Abstract Image

Nanozymes, which can selectively scavenge reactive oxygen species (ROS), have recently emerged as promising candidates for treating ischemic stroke and traumatic brain injury (TBI) in preclinical models. ROS overproduction during the early phase of these diseases leads to oxidative brain damage, which has been a major cause of mortality worldwide. However, the clinical application of ROS-scavenging enzymes is limited by their short in vivo half-life and inability to cross the blood-brain barrier. Nanozymes, which mimic the catalytic function of natural enzymes, have several advantages, including cost-effectiveness, high stability, and easy storage. These advantages render them superior to natural enzymes for disease diagnosis and therapeutic interventions. This review highlights recent advancements in nanozyme applications for ischemic stroke and TBI, emphasizing their potential to mitigate the detrimental effect of ROS overproduction, oxidative brain damage, inflammation, and blood-brain barrier compromise. Therefore, nanozymes represent a promising treatment modality for ROS overproduction conditions in future medical practices.

Three quick tests to find out if you are at risk of falling

 If your therapist gives you these tests and you don't have followup interventions to prevent falls; then you don't have a functioning therapist.

Three quick tests to find out if you are at risk of falling

It takes less than three minutes to complete these!

First Test: Single leg stance or “One-legged stance test”

  1. Performed with eyes open and arms on the hips.
  2. The participant must stand unassisted on one leg and is timed in seconds from the time one foot is flexed off the floor to the time when it touches the ground or the standing leg or an arm leaves the hip.
  3. Participants unable to perform the one-leg stand for at least 5 seconds are at increased risk for injurious fall.

On my good leg I can do this, my bad leg not even close. Since I haven't been able to do this since my stroke at age 50 I guess I should have died sometime in the ensuing 18 years. I thought the Berg Balance Scale testing  that was common, was totally worthless since there never was any specific therapy given to address the failure points I had in that test.

 

Second Test: Timed Up and Go (TUG) text

  1. The participants wear their regular footwear and can use a walking aid if needed. Begin by having them sit back in a standard arm chair and identify a line 3 meters or 10 feet away on the floor.
  2. With the cue of “GO”, the participants stand up from the chair, walk to the line on the floor at your NORMAL pace, turn, walk back to the chair at your NORMAL pace, then sit down again.
  3. Time the pace of walking
  4. An older adult who takes more than 12 seconds to complete the TUG is at high risk for falling.
I could easily do this while still in the hospital.

Third Test: Functional Reach Test

  1. The participant stands side way against a wall where you keep a yard stick at the shoulder level. He/she stands with his/her feet shoulder apart with one arm flexed at 90 degree at the shoulder level with elbow straight.
  2. Measure an initial reading on the yard stick.
  3. Ask the participant to reach forward as much as he/she can to reach.
  4. Measure the final reading on the yard stick. The initial reading is subtracted from the final to obtain the functional reach score.
  5. A score of 6 or less inches indicates a significant increased rick of falls.
  6. A score between 6-10 inches indicates a moderate risk for falls.
I can do about 12 inches.

Treatment for intracerebral hemorrhage: Dawn of a new era

 This is why we need survivors in charge, we wouldn't give up. You better wait a couple of decades before you have your intracerebral hemorrhage stroke

Treatment for intracerebral hemorrhage: Dawn of a new era

Abstract

Intracerebral hemorrhage (ICH) is a devastating disease, causing high rates of death, disability, and suffering across the world. For decades, its treatment has been shrouded by the lack of reliable evidence, and consequently, the presumption that an effective treatment is unlikely to be found. Neutral results arising from several major randomized controlled trials had established a negative spirit within and outside the stroke community. Frustration among researchers and a sense of nihilism in clinicians has created the general perception that patients presenting with ICH have a poor prognosis irrespective of them receiving any form of active management. All this changed in 2023 with the positive results on the primary outcome in randomized controlled trials showing treatment benefits for a hyperacute care bundle approach (INTERACT3), early minimal invasive hematoma evacuation (ENRICH), and use of factor Xa-inhibitor anticoagulation reversal with andexanet alfa (ANNEXa-I). These advances have now been extended in 2024 by confirmation that intensive blood pressure lowering initiated within the first few hours of the onset of symptoms can substantially improve outcome in ICH (INTERACT4) and that decompressive hemicraniectomy is a viable treatment strategy in patients with large deep ICH (SWITCH). This evidence will spearhead a change in the perception of ICH, to revolutionize the care of these patients to ultimately improve their outcomes. We review these and other recent developments in the hyperacute management of ICH. We summarize the results of randomized controlled trials and discuss related original research papers published in this issue of the International Journal of Stroke. These exciting advances demonstrate how we are now at the dawn of a new, exciting, and brighter era of ICH management.

Intracerebral hemorrhage—the deadly sibling of ischemic stroke

Intracerebral hemorrhage (ICH) is caused by the rupture of cerebral vessels which results in bleeding within the brain parenchyma and/or ventricles.1 Overall, ICH comprises approximately 10–15% of all strokes worldwide, but the rates are higher in low- and middle-income countries.2 Compared to ischemic stroke, the incidence of ICH has increased in recent years and the prognosis remains poor.3,4 Current estimates predict a significant increase in the incidence of ICH in Europe related to aging and greater use of anticoagulants, with major implications for health care systems and societies.5

Treatment of ICH before 2023—widespread frustration and nihilism

For decades, treatment of ICH has been overshadowed by limited evidence and a presumed lack of effective treatment options reflected by neutral and restrictive guideline recommendations.6,7 Several randomized controlled trials of surgical treatment (i.e. different approaches to evacuation of parenchymal or intraventricular hematoma),811 blood pressure (BP) control,12,13 and hemostatic therapies,1416 resulted in either borderline significant or neutral results. The evidence was persuasive from INTERACT2,12 and stronger when pooled with other trials as part of an individual patient data meta-analysis,17 for a beneficial effect of early intensive BP lowering. Although a study-level meta-analysis of hematoma evacuation also found a potential benefit,18 there is ongoing uncertainty over which patients have the most to gain from neurosurgery along with the optimal timing and technique of intervention. Collectively, these efforts have contributed to somewhat of a negative spirit within (and outside) the stroke community, and in turn degrees of frustration and nihilism regarding treatment approaches and the perception of a uniformly poor prognosis for patients with ICH.19
 
More at link.